Treating an Advanced Combined Hepatocellular-Cholangiocarcinoma with a Multikinase Inhibitor.
| Autor: | Fraga T; Medical Oncology, Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, PRT., Bonito N; Medical Oncology, Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, PRT. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Feb 01; Vol. 16 (2), pp. e53394. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.53394 |
| Abstrakt: | Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is an aggressive hepatic cancer that has characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). For resectable disease, liver resection is the preferred first treatment option. As for the advanced or metastatic setting, and due to its rarity, there is still no consensus on which is the optimal systemic treatment. As such, regimens used in both HCC and CC have often been used as first-line treatment options. We report a case of a male patient in his 50s, diagnosed with a cHCC-CC with lymph node and adrenal metastasis, with an extensive portal vein tumour thrombosis, that started treatment with a multikinase inhibitor - lenvatinib. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Fraga et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|